Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL. Konecny GE, et al. Among authors: hamidi h. J Natl Cancer Inst. 2014 Sep 30;106(10):dju249. doi: 10.1093/jnci/dju249. Print 2014 Oct. J Natl Cancer Inst. 2014. PMID: 25269487 Free PMC article.
Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, Song H, Dicks EM, Harrington P, Wick M, Winterhoff BJ, Hamidi H, Konecny GE, Chien J, Bibikova M, Fan JB, Kalli KR, Lindor NM, Fridley BL, Pharoah PP, Goode EL. Cunningham JM, et al. Among authors: hamidi h. Sci Rep. 2014 Feb 7;4:4026. doi: 10.1038/srep04026. Sci Rep. 2014. PMID: 24504028 Free PMC article.
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.
Cicek MS, Koestler DC, Fridley BL, Kalli KR, Armasu SM, Larson MC, Wang C, Winham SJ, Vierkant RA, Rider DN, Block MS, Klotzle B, Konecny G, Winterhoff BJ, Hamidi H, Shridhar V, Fan JB, Visscher DW, Olson JE, Hartmann LC, Bibikova M, Chien J, Cunningham JM, Goode EL. Cicek MS, et al. Among authors: hamidi h. Hum Mol Genet. 2013 Aug 1;22(15):3038-47. doi: 10.1093/hmg/ddt160. Epub 2013 Apr 9. Hum Mol Genet. 2013. PMID: 23571109 Free PMC article.
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y, Wu AC, Harrington BS, Davies CM, Wallace SJ, Adams MN, Palmer JS, Roche DK, Hollier BG, Westbrook TF, Hamidi H, Konecny GE, Winterhoff B, Chetty NP, Crandon AJ, Oliveira NB, Shannon CM, Tinker AV, Gilks CB, Coward JI, Lumley JW, Perrin LC, Armes JE, Hooper JD. He Y, et al. Among authors: hamidi h. Oncogene. 2016 Jan 28;35(4):468-78. doi: 10.1038/onc.2015.101. Epub 2015 Apr 20. Oncogene. 2016. PMID: 25893298
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett SM, Slamon DJ. Garon EB, et al. Among authors: hamidi h. Mol Cancer Ther. 2013 Jun;12(6):890-900. doi: 10.1158/1535-7163.MCT-12-0998. Epub 2013 Mar 14. Mol Cancer Ther. 2013. PMID: 23493311 Free PMC article.
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF. Logan JE, et al. Among authors: hamidi h. Anticancer Res. 2013 Aug;33(8):2997-3004. Anticancer Res. 2013. PMID: 23898052
133 results